IRIS (International Remote Imaging Systems) signs letter of intent for sale of unit:
This article was originally published in Clinica
Executive Summary
International Remote Imaging Systems (IRIS) has signed a letter of intent with an unnamed international company for the sale of its Perceptive Scientific Instruments subsidiary for between $2.5 million and $5 million. The division makes and markets the PowerGene line of genetic analysers. The Chatsworth, California-based company announced plans to refocus operations on its core urinalysis business and write off assets relating to non-core operations (see Clinica No 885, p 12). IRIS intends to develop lower-cost, faster imaging products.
You may also be interested in...
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
Irish Body Sets Out Five-Year Vision Strategy For Off-Patent Sector
With a focus on drug accessibility, supply chain resilience, and a balanced approach to sustainability, Medicines for Ireland “calls to action” with its five-year plan.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.